Venus Remedies secures firstiInternational market authorization for Sugammadex from the Philippines
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
Subscribe To Our Newsletter & Stay Updated